Skip to main content
    E

    Elicio Therapeutics Inc. (ELTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.51
    +0.11 (+7.86%)

    Market Cap: $37.93M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(7/17)
    Avg Surprise
    -14.72%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.46
    Range$-0.74 - $-0.27
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Last 12 of 22 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.46$-0.74 - $-0.27--4--
    Sep 26
    Reported Nov 5
    		$-0.30$-0.42$-0.48 - $-0.40+28.57%Beat4
    No revisions (30d)
    		+50.0%
    Jun 26
    Reported Aug 13
    		$-0.43$-0.53$-0.60 - $-0.45+18.87%Beat4
    No revisions (30d)
    		+34.8%
    Mar 26
    Reported May 11
    		$-0.65$-0.46$-0.49 - $-0.44-41.30%Miss2
    0
    1
    30d
    		+25.3%
    Dec 25
    Reported Mar 12
    		$-0.49$-0.45$-0.47 - $-0.42-10.11%Miss2
    1
    0
    30d
    		+52.0%
    Sep 25
    Reported Nov 13
    		$-0.60$-0.48$-0.48 - $-0.48-25.00%Miss1
    0
    1
    30d
    		+56.8%
    Jun 25
    Reported Aug 7
    		$-0.66$-0.69$-0.69 - $-0.68+4.35%Beat2
    No revisions (30d)
    		-3.1%
    Mar 25
    Reported May 13
    		$-0.87$-0.83$-1.15 - $-0.64-4.82%Miss3
    0
    1
    30d
    		+24.3%
    Dec 24
    Reported Mar 31
    		$-1.02$-0.88$-0.99 - $-0.76-16.57%Miss2
    0
    1
    30d
    		+41.7%
    Sep 24
    Reported Nov 13
    		$-1.39$-0.73$-0.95 - $-0.57-90.41%Miss3
    1
    1
    30d
    		-9.4%
    Jun 24
    Reported Aug 13
    		$-0.64$-0.96$-1.04 - $-0.88+33.33%Beat2
    No revisions (30d)
    		+73.7%
    Mar 24
    Reported May 15
    		$-1.15$-1.09$-1.21 - $-0.97-5.50%Miss2
    1
    0
    30d
    		+23.7%
    Dec 23
    Reported Feb 13
    		$-1.75$-0.78$-1.03 - $-0.54-124.36%Miss2
    No revisions (30d)
    		+16.7%

    Key Metrics

    Valuation
    P/E Ratio-0.81EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-775.00%ROIC-96.64%
    Financial Health
    Debt/Equity0.51xInterest Coverage-22.24x
    Current Ratio3.43xQuick Ratio3.43x
    Trading Statistics
    Beta2.00Avg Volume324.89K
    52-Week High$16.0052-Week Low$1.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.64
    SMA 20$1.69
    SMA 50$1.91
    SMA 200$6.62
    EMA 10$1.60
    EMA 20$1.69
    EMA 50$2.11
    EMA 200$5.15

    MACD

    Line: -0.12Signal: -0.11Hist: -0.01

    ADX

    ADX: 29.2+DI: 10.2-DI: 28.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down100.0
    PSAR$1.90

    Bollinger Bands

    Upper Band$1.99
    Lower Band$1.39
    %B Position3601%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    39.0

    Momentum Oscillators

    Stoch %K19.3
    Stoch %D17.7
    Williams %R-64.4
    ROC (10d)-20.5%
    Momentum-0.39
    CCI (20d)-147.2
    MFI (14d)44.6

    Volatility Measures

    ATR (14d)$0.19(12.7%)
    StdDev (20d)0.15
    Hist Vol110.4%(High)

    Volume Flow

    VWAP$1.43
    OBV29.8M
    AD Line-20.6M
    CMF (20d)0.020

    Volume Metrics

    Avg Vol (20d)328.7K
    Vol Ratio2.3x(High)
    VWMA (20d)$1.68

    Pivot Points

    R3$1.83
    R2$1.75
    R1$1.57
    Pivot Point$1.49
    S1$1.31
    S2$1.23
    S3$1.05

    Advanced Oscillators

    TSI-22.57
    Ultimate Osc39.9
    KST-125.00

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0$0$0$0$0$0$0$1.17M$0$0$0$0
    Cost of Revenue$0$0$0$286,000$0$0$0$305,000$0$0$0$286,000
    Gross Profit$0$0$0$-286,000$0$0$0$-305,000$0$0$0$-286,000
    Operating Expenses$8.45M$10.43M$10.60M$8.84M$8.04M$10.09M$10.74M$13.48M$10.34M$10.92M$10.24M$9.39M
    R&D$4.89M$6.81M$6.76M$5.08M$5.04M$7.01M$7.78M$10.71M$7.21M$8.18M$7.56M$6.16M
    SG&A$3.56M$3.62M$3.85M$3.76M$3.01M$3.08M$2.96M$2.77M$3.14M$2.74M$2.68M$3.23M
    Operating Income$-8,452,000$-10,429,000$-10,602,000$-8,842,000$-8,045,000$-10,091,000$-10,736,000$-13,477,000$-10,344,000$-10,924,000$-10,241,000$-9,392,000
    Interest Income$237,000$138,000$157,000$199,000$199,000$168,000$210,000$305,000$185,000$137,000$150,000$78,000
    Interest Expense$413,000$410,000$407,000$337,000$426,000$194,000$176,000$233,000$137,000$49,000$36,000$1,000
    Income Before Tax$-7,924,000$-8,217,000$-11,823,000$-7,718,000$-10,083,000$-10,561,000$-11,209,000$-14,004,000$-18,838,000$-7,229,000$-11,827,000$-9,054,000
    Income Tax Expense$55,000$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,979,000$-8,217,000$-11,823,000$-7,718,000$-10,083,000$-10,561,000$-11,209,000$-14,004,000$-18,838,000$-7,229,000$-11,827,000$-8,949,000
    EBITDA$-7,364,000$-7,556,000$-11,262,000$-7,112,000$-9,573,000$-10,254,000$-10,930,000$-13,722,000$-18,570,000$-7,024,000$-11,654,000$-8,845,000
    EBIT$-7,748,000$-7,945,000$-11,573,000$-7,580,000$-9,856,000$-10,535,000$-11,243,000$-14,076,000$-18,886,000$-7,317,000$-11,944,000$-9,131,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELTX

    News

    With $30.9M in cash, Elicio Therapeutics (ELTX) still flags going-concern doubt.

    Elicio Therapeutics (ELTX) reported a third-quarter 2026 net loss of $8.0 million and an accumulated deficit of $261.7 million, with $30.9 million in cash and cash equivalents...

    Stock Titan•11/5/26•Bearish

    Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

    Elicio Therapeutics will host a virtual Key Opinion Leader (KOL) event on November 11, 2026, featuring expert oncologists from Memorial Sloan Kettering Cancer Center. The event will discuss the unmet need in metastatic...

    GlobeNewswire•11/4/26•Somewhat-Bullish

    Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

    Elicio Therapeutics will host a virtual Key Opinion Leader (KOL) event on November 11, 2026, to discuss its investigational immunotherapy, camupepimut (ELI-002 7P)...

    Elicio Therapeutics•11/4/26•Somewhat-Bullish

    Elicio Therapeutics, Inc. (ELTX) Stock Price & News

    Elicio Therapeutics, Inc. (ELTX) is currently trading at US$1.52, down 4.40% as of November 3, 16:00 EST, with a market capitalization of US$79.9M. The company...

    Syfe•11/3/26•Somewhat-Bearish

    Elicio Therapeutics, Inc. (ELTX) Seasonal returns chart

    This article provides a seasonal returns chart for Elicio Therapeutics, Inc. (ELTX), showing the average monthly price return from 2021 to 2026. It includes current stock price information and links to various financial...

    Yahoo Finance UK•10/31/26•Neutral

    ELTX Valuation and Fair Value

    P/E
    -0.8x
    P/B
    2.1x
    See GNG's fair value

    ELTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -96.6%
    ROE
    -775.0%

    ELTX Competitors

    CompanyTicker
    Scynexis IncSCYX
    ETHZilla CorporationETHZ
    eXoZymes, Inc.EXOZ
    Veru IncVERU
    Harvard Bioscience IncHBIO
    Grace Therapeutics, Inc.GRCE
    Hyperion DeFi, Inc.HYPD
    Pelthos Therapeutics Inc.PTHS

    Sector: Healthcare

    ELTX Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ELTX Bull Case vs Bear Case

    Bear case

    • ELTX beat EPS estimates in 37.5% of its last 8 reported quarters.

    ELTX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -5.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.46

    ELTX Earnings Date

    ELTX reports Mar 10, 2027, after the close. The date is estimated.

    ELTX ETF Holders

    GNG tracks 2 ETFs that hold ELTX. The largest weights:

    1. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    2. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for ELTX

    Frequently Asked Questions About ELTX

    When does ELTX report earnings?

    Elicio Therapeutics Inc. (ELTX) is expected to report earnings on Mar 10, 2027.

    Does ELTX pay dividends?

    Elicio Therapeutics Inc. (ELTX) does not currently pay a regular dividend.

    What is ELTX's market cap?

    Elicio Therapeutics Inc. (ELTX) has a market capitalization of $37.93M with a current stock price of $1.51.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In